Alto Neuroscience Stock price
Is Alto Neuroscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.
Key metrics
Alto Neuroscience Stock Analysis
Analyst Opinions
17 Analysts have issued a Alto Neuroscience forecast:
Analyst Opinions
17 Analysts have issued a Alto Neuroscience forecast:
Don't miss a Thing! We will send you all news about Alto Neuroscience directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Alto Neuroscience Stock News
Company Profile
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Los Altos, CA.
| Head office | United States |
| CEO | Dr. Etkin |
| Employees | 68 |
| Founded | 2019 |
| Website | www.altoneuroscience.com |


